chronic obstructive pulmonary disease
Conditions
Interventions
Hochuekkito is administrated in apathetic patients with chronic obstructive pulmonary disease who receive pulmonary rehabilitation
Hochuekkito is not administrated in apathetic patients with chronic o
Sponsors
Hiroshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)COPD stage 2-3, FEV1/FVC<70%, 30%<FEV1 pred<70% 2)Clinically stable COPD 3)Apathy scale score > 16 4)Age: 40 years or older 5)Smoking history > 10 pack-years 6)Patients who will be able to receive treatment for 12 weeks 7)Male or female 8)Patients who will be able to take food orally 9) Patients who will write informed consent
Exclusion criteria
Exclusion criteria: 1)Diagnosed other pulmonary diseases 2)No acute exacerbation within 4 weeks 3)Receiving pulmonary transplantation 4)PHQ-9 score > 15 5) Patients who will not able to walk or perform activities of daily living due to bone and joint diseases or neurological disorders 6)No reciving pulmonary rehabilitation within 24 weeks 7)Receiving inhaled or systemic steroid therapy within 2 weeks 8)Receiving herbal medicine within 4 weeks 9)Engage other clinical trial within 4 weeks 10)Patients who have allergy for herbal medicines 11)alpha1 antitrypsin deficiency 12)Severe other diseases such as malignancy, autoimmune disease, liver disease, renal disease, heart disease, hematologic disease, and metabolic disease 13)Pregnant and nursing 14)Inappropriate patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apathy scale score, Numbers of steps, PHQ-9 score, COPD assessment test score, Modified Medical Research Council dyspnea scale, VAS for dyspnea, VAS for fatigue, Body weight, Body mass index, Rate of acute exacerbation, Hematological data, Adverse events | — |
Countries
Japan
Contacts
Public ContactHiroshi Iwamoto
Hiroshima University Hospital Department of Respiratory Medicine
Outcome results
None listed